Ventyx Biosciences, Inc. (VTYX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VTYX currently has 71.3M outstanding shares. with moderate dilution risk from 18.2M authorized shares representing 25.6% potential dilution. The company has minimally diluted shareholders by 4.28% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 06, 2025 |
10-Q filing | 71.3M shares outstanding |
71M | 18M |
| May 08, 2025 |
10-Q filing | 71.1M shares outstanding |
71M | 18M |
| Feb 27, 2025 |
10-K filing | 68.5M shares outstanding |
68M | 18M |
| Nov 07, 2024 |
S-3 filing: This prospectus covers the offer and resale from time to time of up to 7,060,100 shares of our common stock, par value $0.0001 per share, issuable upon conversion of 70,601 shares of Series A Non-Voting Convertible Preferred Stock |
71M | 18M |
| Nov 07, 2024 |
10-Q filing | 70.7M shares outstanding |
71M | 18M |
| Aug 08, 2024 |
10-Q filing | 70.6M shares outstanding |
71M | 11M |
| May 09, 2024 |
10-Q filing | 70.5M shares outstanding |
70M | 11M |
| Apr 09, 2024 |
S-3 filing: Ventyx Biosciences, Inc. is offering 11,174,000 shares of common stock by selling stockholders. |
59M | 11M |
| Feb 28, 2024 |
POS AM filing: This POS AM filing by Ventyx Biosciences, Inc. describes a shelf offering of common stock, preferred stock, and debt securities with an aggregate offering price not to exceed $300 million. |
59M | 0 |
| Feb 27, 2024 |
10-K filing | 58.5M shares outstanding |
59M | 0 |
| Nov 09, 2023 |
10-Q filing | 58.9M shares outstanding |
59M | 0 |
| Aug 10, 2023 |
10-Q filing | 58.6M shares outstanding |
59M | 0 |
| May 11, 2023 |
10-Q filing | 57.6M shares outstanding |
58M | 0 |
| Mar 23, 2023 |
10-K filing | 52.5M shares outstanding |
52M | 0 |
| Dec 20, 2022 |
POS AM filing: This prospectus covers the offer and resale from time to time of up to 5,350,000 shares of common stock of Ventyx Biosciences, Inc. by the selling stockholders. |
52M | 0 |
| Nov 04, 2022 |
10-Q filing | 51.7M shares outstanding |
52M | 5.4M |
| Sep 27, 2022 |
S-1 filing: The filing relates to the offer and resale of 5,350,000 shares of common stock by selling stockholders. |
51M | 5.4M |
| Aug 15, 2022 |
10-Q filing | 50.8M shares outstanding |
51M | 0 |
| May 12, 2022 |
10-Q filing | 50.9M shares outstanding |
51M | 0 |
| Mar 24, 2022 |
10-K filing | 50.7M shares outstanding |
51M | 0 |
| Nov 18, 2021 |
10-Q filing | 50.3M shares outstanding |
50M | 0 |
| Oct 25, 2021 |
8-K filing: Ventyx Biosciences, Inc. completed its initial public offering of 10,893,554 shares of its common stock, including the full exercise of the underwriters option to purchase additional shares. |
N/A | 0 |
| Oct 15, 2021 |
S-1/A filing: This is an S-1/A filing for a proposed initial public offering of common stock, including firm shares and optional shares, underwritten by Jefferies LLC, Evercore Group L.L.C., Piper Sandler & Co., and LifeSci Capital LLC. The document includes representations, warranties, and covenants related to the offering and the company's operations. |
N/A | 0 |
| Oct 14, 2021 |
S-1/A filing: Initial public offering of common stock with an expected price range to be determined. Shares will be listed on the Nasdaq Global Market under the symbol "VTYX". |
N/A | 0 |
| Sep 29, 2021 |
S-1 filing: This S-1 filing relates to a proposed initial public offering of common stock, with a total proposed amount of $100,000,000. |
N/A | 0 |